Aug. 6, 2013
/PRNewswire/ -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of
on behalf of investors who purchased Dynavax Technologies Corporation ("Dynavax" or the "Company") (Nasdaq: DVAX) stock between
April 26, 2012
June 10, 2013
For more information, click here:
The complaint alleges that defendants violated federal securities laws by issuing materially false and misleading statements concerning the viability of their drug HEPLISAV. In particular, it is alleged that during the Class Period Dynavax concealed from the public that: (1) the clinical trial for HEPLISAV was flawed because it was not representative of the US population and lacked information regarding concomitant use of HEPLISAV with other vaccines; (2) Dynavax failed to provide the FDA with sufficient data concerning its manufacturing processes and controls for HEPLISAV.
June 10, 2013
, Dynavax disclosed that the FDA required additional data regarding the safety of HEPLISAV before it could further review the drug for potential approval.
If you suffered a loss in Dynavax you have until
August 19, 2013
to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact
Joseph E. Levi, Esq.
either via email at
or by telephone at (877) 363-5972, or visit
Levi & Korsinsky is a national firm with offices in
, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY
10004 Tel: (212) 363-7500Toll Free: (877) 363-5972Fax: (866) 367-6510
SOURCE Levi & Korsinsky, LLP